Technology Development Recent Happenings

Inventors Recognition Program

In the second half of FY 2016, and the first half of FY 2017, NIAID recognized the following individuals for their contributions to the first U.S. patents issued in a patent family.

United States patent 9,353,353 was issued on May 31, 2016 for Virus-like particles (VLPs) prepared from chikungunya virus structural proteins.  NIAID inventors: Srinivas Rao, DVM, PhD, MBA

United States patent 9,320,786 was issued on April 26, 2016, for Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria.  NIAID inventors: Sanjay A. Desai, M.D., Ph.D.

United States patent 9,365,626 was issued on June 14, 2016 for Simukunin. NIAID inventor: Ivo Francischetti, MD, PHD (no longer at NIH)

United States patent 9,375,424 was issued on June 28, 2016 for Compounds that treat malaria and prevent malaria transmission. NIAID inventors:  Xinzhuan Su, PhD  

United States patent 9,441,019 was issued on September 13, 2016 for Influenza hemagglutinin protein-based vaccines NIAID inventor: Peter Kwong, PH.D.,

United States patent 9,453,239 Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes was issued on September 27, 2016 for NIAID Inventors: Bernard Moss, M.D., Ph.D., Linda Wyatt, Ph.D.

United States patent 9,475,862 was issued on October 25, 2016, for Neutralizing GP41 antibodies and their use.  NIAID inventors: Mark Connors, M.D., Peter Kwong, PH.D., John R. Mascola, M.D., Baoshan Zhang, Rebecca S. Rudicell, Yongping Yang, Ph.D.

United States patent 9,481,866 was issued on November 1, 2016, for Methods of producing T cell populations enriched for stable regulatory T-cells NIAID inventor: Ethan Shevach, M.D.

United States patent 9,487,563 was issued on November 8, 2016, for Virus-like particles and methods of use . NIAID inventors: Srinivas Rao, DVM, PhD, MBA

United States patent 9,526,777 was issued on December 27, 2016, for Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein. NIAID inventors: Nancy J.Sullivan, Ph.D., Cheng Cheng

United States patent 9,534,041 was issued on January 3, 2017, for Monoclonal antibodies that neutralize a norovirus .NIAID inventors: Zhaochun Chen, Ph.D., Lisbeth Kim Green, Ph.D., Stanislav Sosnovtsev, Ph.D., Karin Bok, CRNP

United States patent 9,555,064 was issued on January 31, 2017, for Protease-deficient Bacillus anthracis. NIAID inventors: Andrei Pomerantsev, Ph.D. , Stephen H. Leppla, Ph.D.

United States patent 9,624,475 was issued on April 18, 2017, for Genetically stable live attenuated respiratory syncytial virus vaccine and its production. NIAID inventors: Peter L Collins, Ph.D., Cindy L. Luongo, Ph.D., Ursula Buchholz, DVM, Ph.D.

Recent Patents

United States patent 9,382,302 was issued on July 5, 2016 for Lutzomyia longipalpis polypeptides and methods of use.  Jesus Valenzuela, Ph.D., Jose Ribeiro, MD, Ph.D.

United States patent 9,394,316 was issued on July 19, 2016, for Inhibitors of the plasmodial surface anion channel as antimalarials.  NIAID inventors: Sanjay A. Desai, M.D., Ph.D.

United States patent 9,403,872 was issued on August 2, 2016 for Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors. NIAID inventor: Stephen H. Leppla, Ph.D.

United States patent 9,254,319 was issued on August 16, 2016, for Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation. NIAID inventors: Michail Sitkovsky, Ph.D. (no longer at NIH)

United States patent 9,441,041 was issued on September 13, 2016 for Aegyptin and uses thereof. NIAID inventor: Jose Ribeiro, MD, Ph.D , Eric Calvo, Ph.D.

United States patent 9,441,022 was issued on September 13, 2016 for Aegyptin and uses thereof. NIAID inventors: Jose Ribeiro, MD, Ph.D., Eric Calvo, Ph.D.

United States patent 9,481,866 was issued on November 1, 2016, for Methods of producing T cell populations enriched for stable regulatory T-cells. NIAID inventors: Ethan Shevach, Ph.D.;

United States patent 9,499,821 was issued on November 22, 2016 for Preventing or treating viral infection using an inhibitor of the LSD1 protein, a MAO inhibitor or an inhibitor of LSD1 and a MAO inhibitor. NIAID inventors:; Thomas Kristie, Ph.D., Jodi Vogel, Ph.D.

United States patent 9,580,492 was issued on February 28, 2017, for Monoclonal antibodies that neutralize anthrax toxins. NIAID inventors: Zhaochun Chen, PHD, Stephen Leppla ,Ph.D.

Recent Collaborative Agreements

NIAID and GlaxoSmithKline (GSK) signed a cooperative research and development agreement (CRADA) for a Controlled trial for the safety and immunogenicity of vaccines against Plasmodium falciparum.  NIAID principle investigator: Patrick E. Duffy, M.D.

NIAID and Amgen Inc. signed a material cooperative research and development agreement (CRADA) for the Development of a therapeutic for leishmaniasis using Amgen, Inc.'s proprietary antibody.    NIAID principle investigator:  David Sacks, Ph.D.

NIAID and Walter Reed Army Institute of Research (WRAIR) (DoD) signed a research collaboration agreement (RCA) to prepare the EBV glycoprotein vaccines with adjuvants supplied by WRAIR and compare their efficacy in mice and monkeys.  NIAID principle investigator: Jeffrey Cohen, M.D.

NIAID and Matinas BioPharma Holding, Inc. signed a cooperative research and development agreement (CRADA) for Preclinical efficacy evaluation of Matinas Biopharma's encochleated amphotericin B (CAMB) for the treatment of mucosal candidiasis.  NIAID principle investigator: Michail Lionakis, M.D., Sc.D.

NIAID and Merck & Co., Inc. signed a cooperative research and development agreement (CRADA) for Merck's proprietary drug to assess HDACi for improvement in Crohn's Disease.  NIAID principle investigators: Warren Strober, M.D.

NIAID and the University of Illinois signed a human research collaboration agreement (RCA) to explore machine learning and higher dimensional computational modeling approaches to develop classifiers for a variety of clinical outcomes.  NIAID principle investigator: Jeffery Taubenberger, M.D., Ph.D.

NIAID and Walter Reed Army Institute of Research (WRAIR) (DoD), Biomedical Advanced Research and Development Authority (BARDA) (DHHS) signed a research collaboration agreement (RCA) to Research and develop a Zika virus (ZIKV) purified-inactivated vaccine (PIV).  NIAID principle investigator:  NIAID principle investigator: Maria-Cristina Cassetti, Ph.D.

NIAID and George Washington University signed a human research collaboration agreement (RCA) for NIAID’s microRNA sequencing data and collaborator’s target genes in HCV infected human hepatocyte culture system.  NIAID principle investigator:  Patrizia Farci, M.D.

NIAD and Abbott Laboratories, Inc. signed a human research collaboration agreement (RCA) to send HIV+ sample to Abbott labs for sequencing.  NAID principle investigator: Thomas Quinn, M.D., M.Sc.

NIAID and Centers for Disease Control and Prevention (CDC) signed a research collaboration agreement (RCA)  to conduct research on the gene expression and antigen presentation of immune cells from bats infected with various filoviruses .NAID principle investigator: Heinz Feldmann, M.D., Ph.D.

NIAID and Amgen Inc. signed a material cooperative research and development agreement (CRADA) to Investigate the role of IL-36 in commensal-specific immunity using Amgen, Inc.'s proprietary IL-36R blocking antibody and two of its IL-36 based murine models.  NAID principle investigator: Yasmine Belkaid, Ph.D.

NIAID and GenVec, Inc. signed a research collaboration agreement (RCA) to Collaborate with GenVec for placental malaria study.  NAID principle investigator: Patrick E. Duffy, M.D.

NIAID and Avidea Technologies signed a cooperative research and development agreement (CRADA) to investigate and evaluate the use of Avidea’s vaccine technology, for (1) cancer immunotherapy and (2) infectious disease vaccines.  NAID principle investigator: Jeffrey Cohen, M.D.

NIAID and ADMA Biologics signed a cooperative research and development agreement (CRADA) for Identification of high titer Epstein Barr Virus (EBV) immune globulin from human plasma and in vitro and in vivo characterization of the EBV immune globulin. NAID principle investigator: Jeffrey Cohen, M.D.

NIAID and Johns Hopkins University (JHU) signed a human research collaboration agreement (RCA)  to Identify influenza A virus RNA-positive postmortem lung tissue samples to characterize subtypes of influenza A viruses. NAID principle investigator: Jeffery Taubenberger, M.D., Ph.D.

NIAID and Sanofi US Services Inc. signed a cooperative research and development agreement (CRADA) for The use of Sanofi US Service's proprietary nanoparticles for novel immunogens.  NAID principle investigator: Barney Graham, M.D., Ph.D.

NIAID and Vaxart, Inc. signed a research collaboration agreement (RCA) for Reagents and techniques for analysis to guide the design of universal influenza vaccines. NAID principle investigator: Richard Koup , M.D.

NIAID and Patara Pharma signed a research collaboration agreement (RCA) To perform research studies using Patara's compound (cromolyn). NAID principle investigator: Dean Metcalf, M.D.

NIAID and Boston Children's Hospital signed a human research collaboration agreement (RCA) for the transfer of NIAID human samples to Boston Children's Hospital.  NAID principle investigator: Joshua Milner, M.D.

NIAID and Institute of Physiology and Pathophysiology (Germany) signed a research collaboration , agreement (RCA) for RGS16 mouse sperm samples NAID principle investigator: Kirk Druey, M.D.

NIAID and Yale University signed a research collaboration agreement (RCA) for bones from RGS knockout mice generated at NIAID to Yale.  NAID principle investigator: Kirk Druey, M.D.

NIAID and University of North Carolina at Chapel Hill signed a human research collaboration agreement (RCA) To characterize Ebola specific humoral and cellular immune responses in human survivors of infection in relation with virus shedding.  NAID principle investigator: Nancy Sullivan, Ph.D.

NIAID and University of North Carolina at Chapel Hill signed a research collaboration agreement (RCA) to collaborate with Baric laboratory, a world leader in the development of emerging coronavirus reverse genetics, pathogenesis, vaccine testing and mouse models of human disease.  NAID principle investigator: Barney Graham, M.D., Ph.D.

NIAID and US Army Medical Research Institute of Infectious Diseases (USAMRIID) (DoD) signed a research collaboration agreement (RCA) for Zika-ICD Clone/Study direct effects from ZIKV infection and replication dynamically. NAID principle investigator: Alexander Pletnev, Ph.D.

NIAID and University of Washington signed a research collaboration agreement (RCA) for Influenza and coronavirus vaccine development - using Univ. of Washington’s unique self-assembling nanoparticle technology.  NIAID principle investigator: Barney Graham, M.D., Ph.D.

NIAID and ModernaTX, Inc. signed a research collaboration agreement (RCA) to evaluate immunogenicity of a Zika virus mRNA vaccine in non-human; determine efficacy of mRNA vaccine in non-human primates. NIAID principle investigator: Barney Graham, M.D., Ph.D.

NIAID and Rutgers University signed a research collaboration agreement (RCA) To send live mice (RGS4 and RGS5 knock-out) to Dr. Reynold Panettieri at Rutgers.  NIAID principle investigator: Kirk Druey, M.D.

NIAID and University of Michigan signed a human research collaboration agreement (RCA) to determine the frequency (seroprevalence) and clinical characteristics/ risk factors of acute HEV infection among adult patients enrolled in the Acute Liver Failure Study Group (ALFSG) Acute Liver Injury prospective study.  NIAID principle investigator: Patrizia Farci, M.D.

NIAID and University of California-Davis, Duke University signed a research collaboration agreement (RCA) To develop a non-human pregnancy model of Zika infection; evaluate Zika in non-human primates;  vaccinate prior to pregnancy after exposure. NIAID principle investigator: Barney Graham, M.D., Ph.D.

NIAID and PATH Malaria Vaccine Initiative (MVI) signed a human research collaboration agreement (RCA) For testing new high sensitivity RDT kits. NIAID principle investigator: Patrick Duffy, M.D.

NIAID, University of California-Davis, and University of California-San Francisco (UCSF) signed a research collaboration agreement (RCA) on ZIKV primate studies. NIAID principle investigator: Alexander Pletnev, Ph.D.

NIAID and PaxVax, Inc. signed a research collaboration agreement (RCA) on the development of the VRC's proprietary zika virus vaccine candidate.  NIAID principle investigator: Barney Graham, M.D., Ph.D.

NIAID, Tulane University, and University of Pittsburgh signed a research collaboration agreement (RCA) to investigate Potential roles of the Act1 adaptor. NIAID principle investigator: Ulrich Siebenlist, Ph.D.

Content last reviewed on May 17, 2017